Compare Costco Wholesale Corporation (COST) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Costco Wholesale Corporation trades at $942.5 (market cap $422.52B), while Regeneron Pharmaceuticals Inc trades at $796.32 (market cap $83.19B). The key difference: Costco Wholesale Corporation is far larger — about 5.1× Regeneron Pharmaceuticals Inc's market cap, and Costco Wholesale Corporation pays the higher dividend (0.62%). Which is the better fit depends on your goals.
| COST | REGN | |
|---|---|---|
Market Cap | $422.52B | $83.19B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $812.27 |
52-Week Low | $849.63 | $545.94 |
Enterprise Value | $410.66B | $77.90B |
Dividend Yield | 0.62% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $952.75, up 0.52% with neutral technical signals. The company shows steady revenue growth, reaching $275.24B in 2025, and maintains strong profitability with a 3.01% net margin. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Analyst sentiment remains bullish with 65.52% buy ratings and a $1,120 consensus price target, while institutional buying activity continues.
Costco's outlook is positive due to membership fee growth and expansion, though high valuation multiples (P/E 47.93) pose risks. Key opportunities include consistent cash flow generation and market share gains, while risks involve competitive pressures and economic sensitivity. The stock offers long-term growth potential but requires monitoring of valuation metrics.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
